Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Tania Slatter

PositionSenior Lecturer and Academic Leader, Histology, for Otago Micro and Nanoscale Imaging (OMNI)
DepartmentDepartment of Pathology (DSM)
QualificationsBSc MSc(Dist) PhD
Research summaryMolecular pathology with a special interest in cancer, perinatal medicine, and autoimmune disease
Memberships
  • Associate Investigator, Gravida: National Centre for Growth and Development
Clinical
  • Brain cancer
  • Breast cancer
  • Perinatal disease
  • Autoimmune disease

Research

Our goal is to understand how the mechanisms that regulate DNA damage lead to molecular changes that predispose to life-long health effects. For this research we use molecular and histo-pathological techniques in combination with collaborative clinical studies.

Within the Department of Pathology, Dr Slatter works as a member of the Molecular Pathology Group alongside Dr Noelyn Hung and Dr Janice Royds with local, national, and international collaborators.

Specific projects in the laboratory are outlined below:

  • Determining how telomere integrity is controlled in normal cells and how this changes with DNA damage. The goal of this study is to identify cancerous changes, or a predisposition to other diseases early.
  • Identifying and characterising molecular sub-types of brain, breast, and other tumours to provide improved patient management and treatment options. This study identifies acquired and inherited genetic variants and then tests how these variants work toward tumour development, and whether these variants could be targeted for treatment.
  • Investigating DNA damage to the placenta and how this affects fetal and maternal health outcomes. This study is part of the Otago Placental Study in collaboration with the Department of Women's and Children's Health.
  • Investigating DNA damage in autoimmune disease and how this leads to further health complications.

Publications

Slatter, T. L., Hung, N., Campbell, H., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., … Jeffs, A., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2011). Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood, 117(19), 5166-5177. doi: 10.1182/blood-2010-11-321851

Slatter, T. L., Tan, X., Yuen, Y. C., Gunningham, S., Ma, S. S., Daly, E., Packer, S., Devenish, C., Royds, J. A., & Hung, N. A. (2012). The alternative lengthening of telomeres pathway operates in non-neoplastic human cells. Journal of Pathology, 226(3), 509-518. doi: 10.1002/path.2981

Slatter, T., Gifford-Garner, J., Wiles, A., Tan, X., Chen, Y.-J., MacFarlane, M., Sullivan, M., Royds, J., & Hung, N. (2010). Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. American Journal of Pathology, 177(6), 2694-2700. doi: 10.2353/ajpath.2010.100468

Slatter, T. L., Ganesan, P., Holzhauer, C., Mehta, R., Rubio, C., Williams, G., Wilson, M., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2010). p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death & Differentiation, 17, 540-550. doi: 10.1038/cdd.2009.136

Royds, J. A., Al Nadaf, S., Wiles, A. K., Chen, Y.-J., Ahn, A., Shaw, A., Bowie, S., … Braithwaite, A. W., … Hung, N. A., & Slatter, T. L. (2011). The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE, 6(10), e26737. doi: 10.1371/journal.pone.0026737

Chapter in Book - Research

Slatter, T., & Fitches, A. (2013). DNA sequencing. In A. Divan & J. Royds (Eds.), Tools and techniques in biomolecular science. (pp. 66-87). Oxford University Press.

Hung, N., & Slatter, T. (2013). Histopathology in biomolecular research. In A. Divan & J. Royds (Eds.), Tools and techniques in biomolecular science. (pp. 418-437). Oxford, UK: Oxford University Press.

^ Top of page

Journal - Research Article

Ferrandon, S., Saultier, P., Carras, J., Battiston-Montagne, P., Alphonse, G., Beuve, M., … Slatter, T., Hung, N., Royds, J., … Poncet, D. (2013). Telomere profiling: Toward glioblastoma personalized medicine. Molecular Neurobiology, 47(1), 64-76. doi: 10.1007/s12035-012-8363-9

Campbell, H. G., Mehta, R., Neumann, A. A., Rubio, C., Baird, M., Slatter, T. L., & Braithwaite, A. W. (2013). Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene, 32(7), 827-836. doi: 10.1038/onc.2012.102

Hung, N. A., Royds, J. A., & Slatter, T. L. (2013). Molecular markers of glioblastoma and the potential for integration with imaging: The future for assigning prognosis and best treatment strategy. Current Molecular Imaging, 2(2), 107-116. doi: 10.2174/2211555211302020001

Hung, N. A., Hsia, H., Royds, J. A., & Slatter, T. L. (2013). Telomere maintenance mechanisms: Prognostic and therapeutic implications for the pathologist and oncologist. Open Journal of Pathology, 3(1), 10-20. doi: 10.4236/ojpathology.2013.31003

Campbell, H. G., Slatter, T. L., Jeffs, A., Mehta, R., Rubio, C., Baird, M., & Braithwaite, A. W. (2012). Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle, 11(3), 446-450. doi: 10.4161/cc.11.3.19054

Slatter, T. L., Tan, X., Yuen, Y. C., Gunningham, S., Ma, S. S., Daly, E., Packer, S., Devenish, C., Royds, J. A., & Hung, N. A. (2012). The alternative lengthening of telomeres pathway operates in non-neoplastic human cells. Journal of Pathology, 226(3), 509-518. doi: 10.1002/path.2981

Royds, J. A., Al Nadaf, S., Wiles, A. K., Chen, Y.-J., Ahn, A., Shaw, A., Bowie, S., … Braithwaite, A. W., … Hung, N. A., & Slatter, T. L. (2011). The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE, 6(10), e26737. doi: 10.1371/journal.pone.0026737

Slatter, T. L., Hung, N., Campbell, H., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., … Jeffs, A., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2011). Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood, 117(19), 5166-5177. doi: 10.1182/blood-2010-11-321851

Slatter, T., Gifford-Garner, J., Wiles, A., Tan, X., Chen, Y.-J., MacFarlane, M., Sullivan, M., Royds, J., & Hung, N. (2010). Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. American Journal of Pathology, 177(6), 2694-2700. doi: 10.2353/ajpath.2010.100468

Slatter, T. L., Ganesan, P., Holzhauer, C., Mehta, R., Rubio, C., Williams, G., Wilson, M., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2010). p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death & Differentiation, 17, 540-550. doi: 10.1038/cdd.2009.136

Slatter, T. L., Jones, G. T., Williams, M. J. A., van Rij, A. M., & McCormick, S. P. A. (2008). Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. Clinical Genetics, 73, 179-184. doi: 10.1111/j.1399-0004.2007.00940.x

Slatter, T. L., Williams, M. J. A., Frikke-Schmidt, R., Tybjærg-Hansen, A., Morison, I. M., & McCormick, S. P. A. (2006). Promoter haplotype of a new ABCA1 mutant influences expression of familial hypoalphalipoproteinemia. Atherosclerosis, 187, 393-400.

More publications...